NASDAQ:XBIT

XBiotech Q3 2026 Earnings Results & Report

XBiotech logo
$1.78 -0.07 (-3.78%)
Closing price 04:00 PM Eastern
Extended Trading
$1.77 -0.01 (-0.56%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XBiotech missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.15 versus the $0.02 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

XBiotech EPS Results

Actual EPS
-$0.15
Consensus EPS
$0.02
Beat/Miss
Missed by -$0.17
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
N/A
Expected Revenue
$7 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Q3 2026 Earnings FAQ

XBiotech (NASDAQ:XBIT) reported earnings of -$0.15 per share for Q3 2026, missing the consensus estimate of $0.02. The report was announced on Thursday, November 12, 2026.

XBiotech Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT) is a biopharmaceutical company based in Austin, Texas, that discovers and develops antibody-based therapies. Its approach uses “True Human” antibodies derived from naturally occurring human immune responses, with the goal of developing treatments for serious diseases.

The company’s research has included antibody candidates for cancer and inflammatory conditions. One of its best-known candidates is bermekimab, an antibody that targets interleukin-1 alpha, a protein involved in inflammation. XBiotech has also pursued other therapeutic programs as part of its drug-development work.

Founded in 2005, XBiotech conducts research and clinical development to advance its antibody therapies. John Simard founded the company and has served as its chief executive officer.

View XBiotech Profile